Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

Investigational New Drugs

Volumn 32, Issue 6, 2014, Pages 1213-1225

  Gopal, Ajay K ^a   Tarantolo, Stefano R ^b   Bellam, Naresh ^c   Green, Damian J ^a   Griffin, Melissa ^a   Feldman, Tatyana ^d   Mato, Anthony R ^d   Eisenfeld, Amy J ^e   Stromatt, Scott C ^e   Goy, Andre ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Methodist Hospital Omaha   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e Emergent Biosolutions   (United States)

Author keywords

Bendamustine; NHL; Otlertuzumab; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CD37 PROTEIN, HUMAN; CHLORMETHINE DERIVATIVE; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OTLERTUZUMAB; RITUXIMAB; TETRASPANIN; TUMOR ANTIGEN;

AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; HUMAN; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; RECOMBINANT FUSION PROTEINS; TETRASPANINS; TREATMENT OUTCOME;

EID: 84938689653     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0125-2     Document Type: Article

References (39)

1. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23(15):3383-3389. doi: 10.1200/JCO.2005.08.100
2. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26(27):4473-4479. doi: 10.1200/JCO.2008.17.0001
3. Fowler NH, Advani RH, Sharman JP, Smith SM, McGreivy J, Kunkel L, Troung V, Zhou C, Boyd TE (2013) The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma American Society of Hematology Annual Meeting; December 7-10, 2013; New Orleans, LA
4. Witzig TE (2005) Current treatment approaches for mantle-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23(26):6409-6414. doi: 10.1200/JCO.2005.55.017
5. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27(32):5404-5409. doi: 10.1200/JCO.2008.21.1169
6. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 25(2):341-347. doi: 10.1038/leu.2010.226
7. Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, Shimada N, Kobayashi K (2010) Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol 92(4):563-570. doi: 10.1007/s12185-010-0707-5
8. Coiffier B (2013) Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma. Clinical lymphoma, myeloma & leukemia 13(4):351-359. doi: 10.1016/j.clml.2013.04.003
9. Bouabdallah K, Ribrag V, Terriou L, Soria JC, Delarue R (2013) Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol 25(Suppl 2):S1-12. doi: 10.1097/CCO.0b013e32835de8ee
10. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. The lancet oncology 12(4):361-368. doi: 10.1016/S1470-2045(11)70062-6
11. Gopal AK, Kahl BS, DeVos S, Wagner-Johnston ND, Schuster SJ, Blum KA, Wojciech JJ, Flinn IW, Flowers CR, Martin P, Viardot A, Goy A, Davies A, Zinzani PL, Dreyling M, Holes LM, Li D, Dancey R, Godfrey WR, Salles GA (2013) Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell Non-Hodgkin lymphoma (iNHL). Blood 122(21):85
12. Rezvani AR, Maloney DG (2011) Rituximab resistance. Best Pract Res Clin Haematol 24(2):203-216. doi: 10.1016/j.beha.2011.02.009
13. Byrd J, Lapalombella R, Ramanunni A, Andritsos L, Flynn J, Baum P, Thompson P, Muthusamy N (2009) Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27:15S
14. Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M, Romero M, Perdiguer L, Delgado M, Orfao A, Lazo PA (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 19(8):1376-1383. doi: 10.1038/sj.leu.2403822
15. Belov L, de la Vega O, dos Remedios CG, Mulligan SP, Christopherson RI (2001) Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 61(11):4483-4489
16. Campo E, Cardesa A, Alos L, Palacin A, Cobarro J, Traserra J, Montserrat E (1991) Non-Hodgkin's lymphomas of nasal cavity and paranasal sinuses. An immunohistochemical study American journal of clinical pathology 96(2):184-190
17. Carbone A, Pinto A, Gloghini A, Volpe R, Zagonel V (1992) B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders. Hum Pathol 23(4):438-448
18. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110(7):2569-2577. doi: 10.1182/blood-2006-12-062927
19. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM (2008) Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112(3):830-835. doi: 10.1182/blood-2008-01-132142
20. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, Keating M, Albitar M (2003) Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 102(10):3514-3520. doi: 10.1182/blood-2003-01-0055
21. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP (2003) An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101(3):1071-1079. doi: 10.1182/blood-2002-03-0876
22. Baum PR, Cerveny C, Gordon B (2009) Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. J Clin Oncol 27(15):8571
23. Algate PW, J.; Nilsson, C.; Sho, M.; Chao, D.; Starling, GC; Byrd, JC, Gordon, B. (2010) TRU-016, An Anti-CD37 SMIPTM Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma. Blood 116:3931
24. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR (2014) A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 123(9):1302-1308. doi: 10.1182/blood-2013-07-512137
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25(5):579-586. doi: 10.1200/JCO.2006.09.2403
26. Ellis S, Carroll KJ, Pemberton K (2008) Analysis of duration of response in oncology trials. Contemporary clinical trials 29(4):456-465. doi: 10.1016/j.cct.2007.10.008
27. Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, Iacoviello L, Donati MB (2010) Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 115(26):5322-5328. doi: 10.1182/blood-2010-01-258624
28. Al-Sharabati M, Chittal S, Duga-Neulat I, Laurent G, Mazerolles C, Al-Saati T, Brousset P, Delsol G (1991) Primary anterior mediastinal B-cell lymphoma. A clinicopathologic and immunohistochemical study of 16 cases. Cancer 67(10):2579-2587
29. Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA, Levy R (1986) A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 137(9):3013-3018
30. Moore K, Cooper SA, Jones DB (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol 152(1):13-21. doi: 10.1002/path.1711520103
31. Norton AJ, Isaacson PG (1987) Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. The American journal of pathology 128(2):225-240
32. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA (1987) Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. The American journal of pathology 128(1):181-201
33. Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein Journal of immunology 140(3):905-914
34. Schuurman HJ, van Baarlen J, Huppes W, Lam BW, Verdonck LF, van Unnik JA (1987) Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology The American journal of pathology 129(1):140-151
35. Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21(5):694-708. doi: 10.1016/j.ccr.2012.03.040
36. Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115-123. doi: 10.1053/j.seminhematol.2010.01.011
37. Leoni LM, Hartley JA (2011) Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 48(Suppl 1):S12-23. doi: 10.1053/j.seminhematol.2011.03.003
38. Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27(9):1492-1501. doi: 10.1200/JCO.2008.18.7252
39. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent L (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203-1210. doi: 10.1016/S0140-6736(12)61763-2